Mestag harnesses new insights into fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases. We are progressing a unique pipeline of novel antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology.
Mestag Therapeutics
Mestag Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £30m
- mestagtherapeutics.com
- Update Information
More venture news
- 5 May 2026
NunaBioNunaBio raises £6.5m led by Northstar Ventures to manufacture high fidelity synthetic DNA at scale
EquityLife Sciences - 5 May 2026
Cytospire TherapeuticsCytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Series ALife Sciences - 30 Apr 2026
BioOrbitBioOrbit lands a £9.8m seed round co-led by LocalGlobe and Breega to manufacture pharmaceutical drugs in space
SeedLife Sciences
